Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Monopar Therapeutics Inc (MNPR)

4.89   0.02 (0.41%) 11-27 01:19
Open: 4.9308 Pre. Close: 4.87
High: 4.96 Low: 4.86
Volume: 5,614 Market Cap: 56M
Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.972 - 5.004 5.004 - 5.034
Low: 4.778 - 4.82 4.82 - 4.859
Close: 4.825 - 4.891 4.891 - 4.951

Technical analysis

as of: 2020-11-25 4:41:37 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 6.14     One year: 7.18
Support: Support1: 4.65    Support2: 4.28
Resistance: Resistance1: 5.26    Resistance2: 6.14
Pivot: 4.79
Moving Average: MA(5): 4.98     MA(20): 4.72
MA(100): 5.78     MA(250):
MACD: MACD(12,26): 0.02     Signal(9): -0.02
Stochastic oscillator: %K(14,3): 61.90     %D(3): 69.78
RSI: RSI(14): 50.79
52-week: High: 48.00  Low: 4.28  Change(%): -81.5
Average Vol(K): 3-Month: 2096  10-Days: 2092

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
MNPR has closed below upper band by 41.5%. Bollinger Bands are 3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sun, 22 Nov 2020
Monopar Therapeutics Inc. - Consensus Indicates Potential 498.5% Upside - DirectorsTalk Interviews

Thu, 12 Nov 2020
Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update - GlobeNewswire

Mon, 09 Nov 2020
Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive® - GlobeNewswire

Wed, 19 Aug 2020
Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19 - GlobeNewswire

Wed, 12 Aug 2020
Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology - GlobeNewswire

Mon, 10 Aug 2020
Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19 - GlobeNewswire

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Neutral Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Neutral
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 11
Shares Float (M) 2
% Held by Insiders 73.46
% Held by Institutions 0.51
Shares Short (K) 42
Shares Short P. Month (K) 46

Stock Financials

EPS -0.421
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 0.500
Profit Margin
Operating Margin
Return on Assets (ttm) -29.4
Return on Equity (ttm) -48.7
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M) -4
Levered Free Cash Flow (M) -2

Stock Valuations

PE Ratio -11.62
PEG Ratio
Price to Book value 9.78
Price to Sales
Price to Cash Flow -12.71

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.